The Technology Development Board (TDB), under the Department of Science & Technology, Government of India, has extended financial assistance to OrthoGraft Pvt. Ltd., Vadodara, for commercializing advanced tissue-derived biological dressings for wound care applications. The support will enable the company to establish manufacturing capabilities for indigenous biological dressings intended for clinical wound-care applications including chronic wounds, diabetic foot ulcers, and burns.
OrthoGraft is a DPIIT-recognised medical device startup developing proprietary technologies for processing viable human tissue into shelf-stable tissue substitutes while retaining key biological and structural characteristics relevant to wound healing. The company's advanced tissue-processing methodology achieves effective cellular removal while preserving tissue quality and bioactive components, resulting in dressings with improved tensile strength, maximal retention of bioactive factors, and Moisture Vapour Transmission Rate comparable to commercially available moist wound dressings.
With TDB assistance, OrthoGraft will strengthen its production infrastructure at the Savli Technology Business Incubator, Government of Gujarat, Vadodara, where the company has leased a bio-incubation facility. The company has obtained requisite licences from CDSCO for manufacture of medical devices for testing purposes and is exploring collaborations with tertiary-care hospitals and medical institutions for further development and clinical translation. OrthoGraft currently holds two granted US patents and is working with institutions including IIT Ropar and multispecialty hospitals towards technology development and translation.
TDB Secretary Shri Rajesh Kumar Pathak stated that advanced biomaterials and tissue-engineered products represent an important frontier for India's medical technology ecosystem, and this support aims to enable an Indian startup to translate its tissue-processing know-how into commercially manufacturable wound-care products. The company leadership expressed that the assistance will help establish dedicated production capabilities and accelerate translation of their proprietary tissue-processing platform into clinically relevant products.